vs
Side-by-side financial comparison of RHYTHM PHARMACEUTICALS, INC. (RYTM) and TRICO BANCSHARES (TCBK). Click either name above to swap in a different company.
TRICO BANCSHARES is the larger business by last-quarter revenue ($109.4M vs $57.3M, roughly 1.9× RHYTHM PHARMACEUTICALS, INC.). TRICO BANCSHARES runs the higher net margin — 251.6% vs -83.0%, a 334.6% gap on every dollar of revenue. On growth, RHYTHM PHARMACEUTICALS, INC. posted the faster year-over-year revenue change (36.9% vs 9.0%). Over the past eight quarters, RHYTHM PHARMACEUTICALS, INC.'s revenue compounded faster (48.5% CAGR vs 5.4%).
Rhythm Pharmaceuticals is a biopharmaceutical firm focused on developing and commercializing targeted therapies for rare genetic disorders causing severe unmanageable obesity, including POMC deficiency, LEPR deficiency, and Bardet-Biedl syndrome. It serves patients in North America and Europe who lack effective standard treatments for their chronic life-altering conditions.
Trico Bancshares is a U.S.-headquartered regional bank holding company operating Tri Counties Bank. It offers a full range of retail and commercial banking services including deposit products, mortgages, small business loans, and wealth management, primarily serving consumers and SMEs in Northern California.
RYTM vs TCBK — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $57.3M | $109.4M |
| Net Profit | $-47.5M | $33.6M |
| Gross Margin | 91.6% | — |
| Operating Margin | -82.2% | 42.6% |
| Net Margin | -83.0% | 251.6% |
| Revenue YoY | 36.9% | 9.0% |
| Net Profit YoY | -9.6% | 15.8% |
| EPS (diluted) | $-0.73 | $1.02 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $57.3M | $109.4M | ||
| Q3 25 | $51.3M | $107.6M | ||
| Q2 25 | $48.5M | $103.6M | ||
| Q1 25 | $32.7M | $98.6M | ||
| Q4 24 | $41.8M | $100.4M | ||
| Q3 24 | $33.3M | $99.1M | ||
| Q2 24 | $29.1M | $97.9M | ||
| Q1 24 | $26.0M | $98.5M |
| Q4 25 | $-47.5M | $33.6M | ||
| Q3 25 | $-52.9M | $34.0M | ||
| Q2 25 | $-46.6M | $27.5M | ||
| Q1 25 | $-49.5M | $26.4M | ||
| Q4 24 | $-43.3M | $29.0M | ||
| Q3 24 | $-43.6M | $29.1M | ||
| Q2 24 | $-32.3M | $29.0M | ||
| Q1 24 | $-141.4M | $27.7M |
| Q4 25 | 91.6% | — | ||
| Q3 25 | 89.3% | — | ||
| Q2 25 | 88.6% | — | ||
| Q1 25 | 88.8% | — | ||
| Q4 24 | 90.9% | — | ||
| Q3 24 | 88.5% | — | ||
| Q2 24 | 89.9% | — | ||
| Q1 24 | 89.2% | — |
| Q4 25 | -82.2% | 42.6% | ||
| Q3 25 | -102.6% | 43.2% | ||
| Q2 25 | -93.4% | 36.5% | ||
| Q1 25 | -143.7% | 35.8% | ||
| Q4 24 | -98.6% | 38.7% | ||
| Q3 24 | -132.0% | 39.8% | ||
| Q2 24 | -139.2% | 40.0% | ||
| Q1 24 | -538.7% | 38.3% |
| Q4 25 | -83.0% | 251.6% | ||
| Q3 25 | -103.1% | 31.6% | ||
| Q2 25 | -96.1% | 26.6% | ||
| Q1 25 | -151.4% | 26.7% | ||
| Q4 24 | -103.6% | 221.4% | ||
| Q3 24 | -131.2% | 29.3% | ||
| Q2 24 | -110.9% | 29.7% | ||
| Q1 24 | -544.4% | 28.2% |
| Q4 25 | $-0.73 | $1.02 | ||
| Q3 25 | $-0.82 | $1.04 | ||
| Q2 25 | $-0.75 | $0.84 | ||
| Q1 25 | $-0.81 | $0.80 | ||
| Q4 24 | $-0.71 | $0.88 | ||
| Q3 24 | $-0.73 | $0.88 | ||
| Q2 24 | $-0.55 | $0.87 | ||
| Q1 24 | $-2.35 | $0.83 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $388.9M | $157.0M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $139.1M | $1.3B |
| Total Assets | $480.2M | $9.8B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $388.9M | $157.0M | ||
| Q3 25 | $416.1M | $298.8M | ||
| Q2 25 | $291.0M | $314.3M | ||
| Q1 25 | $314.5M | $308.3M | ||
| Q4 24 | $320.6M | $145.0M | ||
| Q3 24 | $298.4M | $320.1M | ||
| Q2 24 | $319.1M | $206.6M | ||
| Q1 24 | $201.2M | $82.8M |
| Q4 25 | $139.1M | $1.3B | ||
| Q3 25 | $148.8M | $1.3B | ||
| Q2 25 | $-11.9M | $1.3B | ||
| Q1 25 | $18.9M | $1.3B | ||
| Q4 24 | $21.7M | $1.2B | ||
| Q3 24 | $11.2M | $1.2B | ||
| Q2 24 | $39.3M | $1.2B | ||
| Q1 24 | $61.6M | $1.2B |
| Q4 25 | $480.2M | $9.8B | ||
| Q3 25 | $506.9M | $9.9B | ||
| Q2 25 | $372.7M | $9.9B | ||
| Q1 25 | $386.7M | $9.8B | ||
| Q4 24 | $392.3M | $9.7B | ||
| Q3 24 | $363.6M | $9.8B | ||
| Q2 24 | $381.8M | $9.7B | ||
| Q1 24 | $258.7M | $9.8B |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-25.4M | $133.3M |
| Free Cash FlowOCF − Capex | — | $127.9M |
| FCF MarginFCF / Revenue | — | 116.9% |
| Capex IntensityCapex / Revenue | — | 4.9% |
| Cash ConversionOCF / Net Profit | — | 3.96× |
| TTM Free Cash FlowTrailing 4 quarters | — | $222.2M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-25.4M | $133.3M | ||
| Q3 25 | $-26.6M | $45.1M | ||
| Q2 25 | $-23.3M | $29.2M | ||
| Q1 25 | $-40.4M | $24.5M | ||
| Q4 24 | $-18.8M | $109.7M | ||
| Q3 24 | $-25.2M | $28.6M | ||
| Q2 24 | $-29.1M | $31.8M | ||
| Q1 24 | $-40.7M | $25.1M |
| Q4 25 | — | $127.9M | ||
| Q3 25 | — | $43.2M | ||
| Q2 25 | — | $28.2M | ||
| Q1 25 | — | $22.8M | ||
| Q4 24 | — | $105.2M | ||
| Q3 24 | — | $27.3M | ||
| Q2 24 | — | $30.8M | ||
| Q1 24 | — | $24.1M |
| Q4 25 | — | 116.9% | ||
| Q3 25 | — | 40.2% | ||
| Q2 25 | — | 27.2% | ||
| Q1 25 | — | 23.1% | ||
| Q4 24 | — | 104.8% | ||
| Q3 24 | — | 27.6% | ||
| Q2 24 | — | 31.5% | ||
| Q1 24 | — | 24.4% |
| Q4 25 | — | 4.9% | ||
| Q3 25 | — | 1.7% | ||
| Q2 25 | — | 1.0% | ||
| Q1 25 | — | 1.7% | ||
| Q4 24 | — | 4.5% | ||
| Q3 24 | — | 1.3% | ||
| Q2 24 | — | 1.0% | ||
| Q1 24 | — | 1.0% |
| Q4 25 | — | 3.96× | ||
| Q3 25 | — | 1.33× | ||
| Q2 25 | — | 1.06× | ||
| Q1 25 | — | 0.93× | ||
| Q4 24 | — | 3.78× | ||
| Q3 24 | — | 0.98× | ||
| Q2 24 | — | 1.10× | ||
| Q1 24 | — | 0.90× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
